|Home | About | Journals | Submit | Contact Us | Français|
Cancer immunotherapy represents one of the most exciting oncologic developments in recent years. Over the course of only several years, basic research has translated into numerous investigational therapies that harness the immune system to treat cancer with and several clinical trials demonstrating excellent outcomes in patients with a variety of malignancies. The great promise of these drugs is countered by several limitations, including challenges in identifying the appropriate disease and patient population within which to test efficacy. In this timely review, Choudhury and Nakamura provide a foundation to understand the mechanisms of cancer immunotherapy and review current applications along with ongoing investigations. The authors help the reader navigate the nuances of the clinical trial literature and outline ongoing efforts to improve patient selection through the use of biomarkers and immunopharmacogenomics.
Significant progress has been made in identifying risk factors for, and the pathogenesis of, gastric cancer. These advances have led to an improvement in the prevention and treatment of this potentially deadly disease, but it continues to be a cause of significant morbidity and mortality worldwide. Previous work has established the role of the Wnt signaling family in the progression of gastric cancer and its relationship to the ECM protein Laminin γ2 may be involved in the development of metastases. In this issue, Ara and colleagues describe their study of how scaffolding proteins interact with the Wnt pathway in the pathogenesis of gastric cancer. The authors show that the protein Daple, which is known to be involved in regulating cell motility, interacts with a scaffolding protein in a process that leads to increased invasion and metastatic features. This exciting work elucidates potential targetable factors in this disease.
Melanoma is a potentially curable disease when identified and treated in its early stages, but metastatic disease has traditionally portended a very poor prognosis. To better understand the process by which melanoma cells develop the ability to metastasize, Kim and coworkers used a combined cell culture and in vivo mouse approach to investigate the role of timosaponin AIII, a phytochemical, in the inhibition of the pathways that promote metastatic potential. The authors describe the therapeutic benefit of timosaponin AIII through its capacity to reduce the metastatic burden of disease by impairing cell migration. They then investigate the molecular mechanism of this effect and identify the suppression of COX‐2 as a key component in this process. This work illustrates the potential therapeutic benefit of this naturally occurring compound in the treatment of melanoma.